
Merck (MRK) Stock Forecast & Price Target
Merck (MRK) Analyst Ratings
Bulls say
Merck & Co is well positioned for growth in the coming years due to a strong portfolio of products targeting diverse therapeutic areas, including cancer, cardiometabolic disease, and infections. The company's leading immuno-oncology platform, Keytruda, is a major contributor to its overall sales and has a high probability of success in various indications, including adjuvant melanoma. Additionally, the company's strong pipeline, with notable programs such as enlicitide and islatravir, supports its growth potential beyond 2028 when Keytruda is expected to face competition. Management's focus on sustainability and diversity initiatives further strengthens the company's long-term outlook.
Bears say
Merck & Co is facing a significant loss in revenue with the impending loss of exclusivity for their top-selling drug, Keytruda, in 2028. While they have a diversified pipeline, their success in replacing Keytruda revenue is uncertain, especially with the recent failure of their Wnt agonist, MK-3000, in diabetic macular edema. Additionally, Merck faces significant risks from their reliance on top pipeline assets, the impact of climate change, and regulatory pressures. This, combined with their high valuation, presents a challenging outlook for the company.
This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.
Merck (MRK) Analyst Forecast & Price Prediction
Start investing in Merck (MRK)
Order type
Buy in
Order amount
Est. shares
0 shares